FDA Grants Fast Track Designation to Amezalpat for Hepatocellular Carcinoma
Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront
Acalabrutinib Plus Venetoclax/Obinutuzumab Demonstrates Efficacy, Safety in Mantle Cell Lymphoma
Experts Comment on the GI/GU Cancer FDA Approvals From 2024